Notably, one drug, LY2584702, which is a selective, adenosine triphosphate (ATP)-competitive p70S6 K inhibitor, has been investigated in clinical trials for the treatment of renal cell carcinoma, metastases, neoplasm, and neuroendocrine tumors—where RPS6KB1 was shown to be implicated in the mechanisms of action of the drug. Here, RPS6KB1 is linked to neoplasm.